Apoprotein composition of plasma lipoproteins in uremic patients on hemodialysis

Staprãns, Ilona; Felts, James M.; Zacherle, Barry J.

doi:10.1016/0009-8981(79)90254-7

Cited by 52 publications

(10 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In haemodialysed patients, we found no correlation between the duration of haemodialysis and the magnitude of serum lipid anomalies, a finding that agrees with another earlier report (36). Serum HDL-phospholipids have already been found to be decreased in uraemic patients treated or untreated by haemodialysis (32,37), whereas apolipoprotein A has been reported to be normal (13,16,19), or decreased (15,17,18) in haemodialysed patients. In the present study, a significant decrease in serum HDL-phospholipids and apolipoprotein A was observed in uraemic patients, with or without haemodialysis.…”

Section: Discussionsupporting

confidence: 90%

See 1 more Smart Citation

Comparison of Several Atherogenicity Indices by the Analysis of Serum Lipoprotein Composition in Patients with Chronic Renal Failure with or without Haemodialysis, and in Renal Transplant Patients

Lacour

Roullet

Beyne

et al. 1985

Clinical Chemistry and Laboratory Medicine

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 90%

“…Only a few studies have been reported with determinations of serum apolipoprotein A (13)(14)(15)(16)(17)(18)(19)(20).…”

Section: Introductionmentioning

confidence: 99%

Comparison of Several Atherogenicity Indices by the Analysis of Serum Lipoprotein Composition in Patients with Chronic Renal Failure with or without Haemodialysis, and in Renal Transplant Patients

Lacour

Roullet

Beyne

et al. 1985

Clinical Chemistry and Laboratory Medicine

View full text Add to dashboard Cite

“…Reasons for decrease in activity of these enzymes are not clear, possibly due to;  Presence of circulatory inhibitor of lipolytic enzymes in the serum  Changes in apoprotein concentrations which can affect lipoprotein lipase activity  Insulin resistance seen in renal insufficiency  Alteration of lipoprotein substrate. 12,13 Hypercholesteremia was found in 32 (22.86%) patients and decrease in HDL cholesterol was found in 30 (21.43%).…”

Section: Discussionmentioning

confidence: 99%

A study of lipid profile in non-diabetic chronic kidney disease

Ganta

Yalamanchi

et al. 2016

Int J Adv Med

View full text Add to dashboard Cite

“…Chronic renal failure is frequently associated with disturbances in lipoprotein transport, alterations in lipoprotein concentration, and abnormalities in lipid and apoprotein composition of lipoproteins [6, 7, 8, 9]. The activities of key enzymes in the lipoprotein metabolism (lipoprotein lipase, hepatic lipase, lecithin-cholesterol acyltransferase) may be diminished [10, 11, 12].…”

Section: Introductionmentioning

confidence: 99%

The Serum Paraoxonase Activity in Patients with Chronic Renal Failure and Hyperlipidemia

Paragh¹,

Serés²,

Balogh³

et al. 1998

Nephron

View full text Add to dashboard Cite

Human serum paraoxonase is physically associated with an apolipoprotein (Apo-A₁) and clusterin-containing high-density lipoprotein (HDL) and prevents low-density lipoprotein from lipid peroxidation. The aim of our study was to determine whether paraoxonase activity or phenotype is altered in patients with chronic renal failure and in hyperlipidemic subjects without renal insufficiency and to compare the values with those of healthy controls. We investigated the serum paraoxonase activity and polymorphism in 119 hemodialyzed uremic patients, 107 patients with primary hyperlipoproteinemia, and in 110 healthy control subjects. The serum paraoxonase activity was significantly decreased both in hyperlipidemic (p < 0.01) and uremic patients (p < 0.001) as compared with controls. On comparison, the serum paraoxonase activity was significantly lower (p < 0.001) in uremic than in hyperlipoproteinemic patients. The HDL and Apo-A₁ levels were as follows: uremic < hyperlipidemic < control. To assess whether the observed reduction in paraoxonase activity was due to HDL and Apo-A₁ level decreases, we standardized the enzyme activity for HDL and Apo-A₁ concentrations. We found that the standardized paraoxonase activity (paraoxonase/HDL ratio) was also lower in the uremic patients (103.3 ± 69.5) as compared with hyperlipidemic patients (137.64 ± 81.0) and controls (194.45 ± 94.45). The standardized values for Apo-A₁ showed a similar tendency: paraoxonase/Apo-A₁ ratio in uremic patients 89.64 ± 47.8, in hyperlipidemic patients 128.12 ± 69.83, and in controls 161.40 ± 47.35. The phenotypic distribution of paraoxonase (AA, AB, BB) did not change significantly in the patient groups. These results suggest that HDL concentration and phenotypic distribution of paraoxonase may not be the only determining factors, but that other as yet undetermined factors could be involved in the enzyme activity changes.

show abstract

Apoprotein composition of plasma lipoproteins in uremic patients on hemodialysis

Cited by 52 publications

References 17 publications

Comparison of Several Atherogenicity Indices by the Analysis of Serum Lipoprotein Composition in Patients with Chronic Renal Failure with or without Haemodialysis, and in Renal Transplant Patients

Comparison of Several Atherogenicity Indices by the Analysis of Serum Lipoprotein Composition in Patients with Chronic Renal Failure with or without Haemodialysis, and in Renal Transplant Patients

A study of lipid profile in non-diabetic chronic kidney disease

The Serum Paraoxonase Activity in Patients with Chronic Renal Failure and Hyperlipidemia

Contact Info

Product

Resources

About